Characterization of antipsychotic medications, amino acid signatures, and platelet-activating factor in first-episode psychosis

First-episode psychosis refers to individuals early in the course of psychotic illness. Identifying the underlying biological processes, including biomarkers, is essential for improving diagnosis and treatment. We performed metabolomics profiling of plasma from a group of first-episode psychosis pat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bracha Erlanger Avigdor, Kun Yang, Ida Shinder, Benjamin C. Orsburn, Rana Rais, Shin-ichi Kano, Akira Sawa, Jonathan Pevsner
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Metabolomics Metabolites Schizophrenia Bipolar disorder Antipsychotics Biomarkers Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
Acceso en línea:	https://doaj.org/article/8ab035f50f2047a1b33dcff5dbfc1af7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8ab035f50f2047a1b33dcff5dbfc1af7
record_format	dspace
spelling	oai:doaj.org-article:8ab035f50f2047a1b33dcff5dbfc1af72021-12-04T04:35:58ZCharacterization of antipsychotic medications, amino acid signatures, and platelet-activating factor in first-episode psychosis2666-144610.1016/j.bionps.2021.100045https://doaj.org/article/8ab035f50f2047a1b33dcff5dbfc1af72021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2666144621000162https://doaj.org/toc/2666-1446First-episode psychosis refers to individuals early in the course of psychotic illness. Identifying the underlying biological processes, including biomarkers, is essential for improving diagnosis and treatment. We performed metabolomics profiling of plasma from a group of first-episode psychosis patients and matched neurotypical controls. Using global metabolomics profiling, we identified antipsychotic or antidepressant medication in 22 individuals diagnosed with first-episode psychosis, closely matching the drug prescription history. There were significant differences in levels of amino acids or their derivatives, including decreases in DL-arginine, L-histidine, DL-serine and threonine as well as increases in L-glutamic acid, ornithine, and proline. Using targeted metabolomics profiling of 408 compounds in plasma samples we identified significant differences in six compounds including decreases in serotonin and arginine as well as increased levels of sarcosine, proline, cis-4-hydroxyproline and trans-4-hydroxyproline. Platelet-activating factor levels were significantly elevated in the FEP cohort. These findings suggest potential biomarkers that require validation in independent cohorts, and in several cases provide supporting evidence for previously reported observations.Bracha Erlanger AvigdorKun YangIda ShinderBenjamin C. OrsburnRana RaisShin-ichi KanoAkira SawaJonathan PevsnerElsevierarticleMetabolomicsMetabolitesSchizophreniaBipolar disorderAntipsychoticsBiomarkersNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571ENBiomarkers in Neuropsychiatry, Vol 5, Iss , Pp 100045- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Metabolomics Metabolites Schizophrenia Bipolar disorder Antipsychotics Biomarkers Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
spellingShingle	Metabolomics Metabolites Schizophrenia Bipolar disorder Antipsychotics Biomarkers Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Bracha Erlanger Avigdor Kun Yang Ida Shinder Benjamin C. Orsburn Rana Rais Shin-ichi Kano Akira Sawa Jonathan Pevsner Characterization of antipsychotic medications, amino acid signatures, and platelet-activating factor in first-episode psychosis
description	First-episode psychosis refers to individuals early in the course of psychotic illness. Identifying the underlying biological processes, including biomarkers, is essential for improving diagnosis and treatment. We performed metabolomics profiling of plasma from a group of first-episode psychosis patients and matched neurotypical controls. Using global metabolomics profiling, we identified antipsychotic or antidepressant medication in 22 individuals diagnosed with first-episode psychosis, closely matching the drug prescription history. There were significant differences in levels of amino acids or their derivatives, including decreases in DL-arginine, L-histidine, DL-serine and threonine as well as increases in L-glutamic acid, ornithine, and proline. Using targeted metabolomics profiling of 408 compounds in plasma samples we identified significant differences in six compounds including decreases in serotonin and arginine as well as increased levels of sarcosine, proline, cis-4-hydroxyproline and trans-4-hydroxyproline. Platelet-activating factor levels were significantly elevated in the FEP cohort. These findings suggest potential biomarkers that require validation in independent cohorts, and in several cases provide supporting evidence for previously reported observations.
format	article
author	Bracha Erlanger Avigdor Kun Yang Ida Shinder Benjamin C. Orsburn Rana Rais Shin-ichi Kano Akira Sawa Jonathan Pevsner
author_facet	Bracha Erlanger Avigdor Kun Yang Ida Shinder Benjamin C. Orsburn Rana Rais Shin-ichi Kano Akira Sawa Jonathan Pevsner
author_sort	Bracha Erlanger Avigdor
title	Characterization of antipsychotic medications, amino acid signatures, and platelet-activating factor in first-episode psychosis
title_short	Characterization of antipsychotic medications, amino acid signatures, and platelet-activating factor in first-episode psychosis
title_full	Characterization of antipsychotic medications, amino acid signatures, and platelet-activating factor in first-episode psychosis
title_fullStr	Characterization of antipsychotic medications, amino acid signatures, and platelet-activating factor in first-episode psychosis
title_full_unstemmed	Characterization of antipsychotic medications, amino acid signatures, and platelet-activating factor in first-episode psychosis
title_sort	characterization of antipsychotic medications, amino acid signatures, and platelet-activating factor in first-episode psychosis
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/8ab035f50f2047a1b33dcff5dbfc1af7
work_keys_str_mv	AT brachaerlangeravigdor characterizationofantipsychoticmedicationsaminoacidsignaturesandplateletactivatingfactorinfirstepisodepsychosis AT kunyang characterizationofantipsychoticmedicationsaminoacidsignaturesandplateletactivatingfactorinfirstepisodepsychosis AT idashinder characterizationofantipsychoticmedicationsaminoacidsignaturesandplateletactivatingfactorinfirstepisodepsychosis AT benjamincorsburn characterizationofantipsychoticmedicationsaminoacidsignaturesandplateletactivatingfactorinfirstepisodepsychosis AT ranarais characterizationofantipsychoticmedicationsaminoacidsignaturesandplateletactivatingfactorinfirstepisodepsychosis AT shinichikano characterizationofantipsychoticmedicationsaminoacidsignaturesandplateletactivatingfactorinfirstepisodepsychosis AT akirasawa characterizationofantipsychoticmedicationsaminoacidsignaturesandplateletactivatingfactorinfirstepisodepsychosis AT jonathanpevsner characterizationofantipsychoticmedicationsaminoacidsignaturesandplateletactivatingfactorinfirstepisodepsychosis
_version_	1718372925788127232

Characterization of antipsychotic medications, amino acid signatures, and platelet-activating factor in first-episode psychosis

Ejemplares similares